HRS-4729 is named as an intervention in 3 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Fujian Shengdi Pharmaceutical Co., Ltd. The most-studied condition is Metabolic Dysfunction-Associated Steatohepatitis (MASH).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis
NCT07660848 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-Associated Steatohepatitis (MASH)
|
Phase 2 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | China |
|
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
NCT07807059 · ClinicalTrials.gov ↗ · Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
|
Phase 1 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | China |
|
A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity
NCT07690826 · ClinicalTrials.gov ↗ · Overweight or Obesity
|
Phase 2 | Not yet open | Fujian Shengdi Pharmaceutical Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Fujian Shengdi Pharmaceutical Co., Ltd. | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China register name HRS-4729 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Fujian Shengdi Pharmaceutical Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how HRS-4729 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how HRS-4729 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists HRS-4729 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.